Back to UBS Group AG UBS Group AG

TBPHTBPH
Showing 8 of 29 quarters

Position history for UBS Group AGUBS Group AG's holdings in THERAVANCE BIOPHARMA INC

UBS Group AG holds 764,105 shares of TBPH (THERAVANCE BIOPHARMA INC), worth $12.4M as of 2026-Q1. The position was increased (+34.0% shares). TBPH represents 0.0% of UBS Group AG's portfolio.

Current Value

$12.4M

Current Shares

764,105

Total Value Change

+$12.1M

Total Shares Change

+730,333

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q1
Latest
Increased
764,105
+34.0%
$12.4M0.0%$13.96
36
2025-Q4
Increased
570,425
+10.9%
$10.7M0.0%$18.91
31
2025-Q3
Increased
514,170
+29.5%
$7.5M0.0%$14.43
34
2025-Q2
Decreased
397,133
-4.9%
$4.4M0.0%$11.22
0
2025-Q1
Increased
417,621
+139.7%
$3.7M0.0%$9.23
43
2024-Q4
Increased
174,245
+466.5%
$1.6M0.0%$9.47
41
2024-Q3
Decreased
30,757
-8.9%
$247,9010.0%$8.10
0
2024-Q2
Decreased
33,772
-42.9%
$286,3870.0%$8.48
0

Other major holders of TBPH: BAUPOST GROUP LLC/MA

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used